INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2019. The put-call ratio across all filers is 2.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $600,000 | +212.5% | 11,467 | -8.0% | 0.00% | +100.0% |
Q1 2020 | $192,000 | -75.6% | 12,467 | -45.7% | 0.00% | -50.0% |
Q4 2019 | $788,000 | -24.0% | 22,967 | -83.4% | 0.00% | -33.3% |
Q3 2019 | $1,037,000 | -51.6% | 138,767 | -15.9% | 0.00% | -40.0% |
Q2 2019 | $2,141,000 | +39.7% | 164,967 | +31.1% | 0.01% | +25.0% |
Q1 2019 | $1,533,000 | +376.1% | 125,867 | +345.3% | 0.00% | +300.0% |
Q4 2018 | $322,000 | – | 28,267 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |